Laboratory-Confirmed Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis of English Data for 2004-2015

Ruth Blackburn, Honxin Zhao, Richard Pebody, Andrew Hayward, Charlotte Warren-Gash, Ruth Blackburn, Honxin Zhao, Richard Pebody, Andrew Hayward, Charlotte Warren-Gash

Abstract

Background: Acute respiratory infections are associated with increased risk of myocardial infarction (MI) and stroke; however, the role of different organisms is poorly characterized.

Methods: Time-series analysis of English hospital admissions for MI and stroke (age-stratified: 45-64, 65-74, ≥75 years), laboratory-confirmed viral respiratory infections, and environmental data for 2004-2015. Weekly counts of admissions were modeled using multivariable Poisson regression with weekly counts of respiratory viruses (influenza, parainfluenza, rhinovirus, respiratory syncytial virus [RSV], adenovirus, or human metapneumovirus [HMPV]) investigated as predictors. We controlled for seasonality, long-term trends, and environmental factors.

Results: Weekly hospital admissions in adults aged ≥45 years averaged 1347 (interquartile range [IQR], 1217-1541) for MI and 1175 (IQR, 1023-1395) for stroke. Respiratory infections ranged from 11 cases per week (IQR, 5-53) for influenza to 55 (IQR, 7-127) for rhinovirus. In the adjusted models, all viruses except parainfluenza were significantly associated with MI and ischemic stroke admissions in those aged ≥75. Among 65- to 74-year-olds, adenovirus, rhinovirus, and RSV were associated with MI but not ischemic stroke admissions. Respiratory infections were not associated with MI or ischemic stroke in people aged 45-64 years, nor with hemorrhagic stroke in any age group. An estimated 0.4%-5.7% of MI and ischemic stroke admissions may be attributable to respiratory infection.

Conclusions: We identified small but strongly significant associations in the timing of respiratory infection (with HMPV, RSV, influenza, rhinovirus, and adenovirus) and MI or ischemic stroke hospitalizations in the elderly.

Clinical trials registration: NCT02984280.

Figures

Figure 1.
Figure 1.
Weekly counts of myocardial infarction (MI) and stroke admissions in England for people aged ≥45 years.
Figure 2.
Figure 2.
Weekly counts of laboratory-confirmed respiratory viruses between 1 April 2004 and 31 March 2015. Abbreviations: HMPV, human metapneumovirus; RSV, respiratory syncytial virus.
Figure 3.
Figure 3.
Weekly observed admissions for myocardial infarction in 65- to 74-year-olds, and the estimated excess admissions attributable to each virus. Abbreviations: MI, myocardial infarction; RSV, respiratory syncytial virus.
Figure 4.
Figure 4.
Weekly observed admissions for myocardial infarction in patients aged >75 years, and the estimated excess admissions attributable to each virus. Abbreviations: HMPV, human metapneumovirus; MI, myocardial infarction; RSV, respiratory syncytial virus.
Figure 5.
Figure 5.
Weekly observed admissions for stroke in patients aged >75 years, and the estimated excess admissions attributable to each virus. Abbreviations: HMPV, human metapneumovirus; RSV, respiratory syncytial virus.
Figure 6.
Figure 6.
Weekly observed admissions for ischemic stroke in patients aged >75 years, and the estimated excess admissions attributable to each virus. Abbreviations: HMPV, human metapneumovirus; RSV, respiratory syncytial virus.

References

    1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388:1459–544.
    1. Levi F, Chatenoud L, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update. Eur J Cardiovasc Prev Rehabil 2009; 16:333–50.
    1. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351:2611–8.
    1. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008; 29:96–103.
    1. Warren-Gash C, Hayward AC, Hemingway H, et al. . Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 2012; 206:1652–9.
    1. Udell JA, Zawi R, Bhatt DL, et al. . Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013; 310:1711–20.
    1. Simonsen L, Viboud C. The art of modeling the mortality impact of winter-seasonal pathogens. J Infect Dis 2012; 206:625–7.
    1. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol 2016; 1:274–81.
    1. Yang L, Ma S, Chen PY, et al. . Influenza associated mortality in the subtropics and tropics: results from three Asian cities. Vaccine 2011; 29:8909–14.
    1. Warren-Gash C, Bhaskaran K, Hayward A, et al. . Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis 2011; 203:1710–8.
    1. Hardelid P, Pebody R, Andrews N. Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999–2010. Influenza Other Respir Viruses 2013; 7:35–45.
    1. Green HK, Andrews N, Fleming D, Zambon M, Pebody R. Mortality attributable to influenza in England and Wales prior to, during and after the 2009 pandemic. PLoS One 2013; 8:e79360.
    1. van Asten L, van den Wijngaard C, van Pelt W, et al. . Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J Infect Dis 2012; 206:628–39.
    1. Fischer WA 2nd, Gong M, Bhagwanjee S, Sevransky J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart 2014; 9:325–36.
    1. Johnson AP. Surveillance of antibiotic resistance. Philos Trans R Soc Lond B Biol Sci 2015; 370:20140080.
    1. Bolton D. The computation of equivalent potential temperature. Mon Weather Rev 1980; 108:1046–53.
    1. Thygesen K, Alpert JS, Jaffe AS, et al. ; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction Third universal definition of myocardial infarction. Circulation 2012; 126:2020–35.
    1. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009; 9:601–10.
    1. Ruane L, Buckley T, Hoo SYS, et al. . Triggering of acute myocardial infarction by respiratory infection. Intern Med J 2017; 47:522–9.
    1. Ludwig A, Lucero-Obusan C, Schirmer P, Winston C, Holodniy M. Acute cardiac injury events </=30 days after laboratory-confirmed influenza virus infection among U.S. veterans, 2010–2012. BMC Cardiovasc Disord 2015; 15:109.
    1. Hebsur S, Vakil E, Oetgen WJ, Kumar PN, Lazarous DF. Influenza and coronary artery disease: exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarction. Rev Cardiovasc Med 2014; 15:168–75.
    1. Kwok CS, Aslam S, Kontopantelis E, et al. . Influenza, influenza-like symptoms and their association with cardiovascular risks: a systematic review and meta-analysis of observational studies. Int J Clin Pract 2015; 69:928–37.
    1. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart 2016; 102:1953–6.
    1. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev 2015; 5:CD005050.
    1. Hsu SY, Chen FL, Liaw YP, Huang JY, Nfor ON, Chao DY. A matched influenza vaccine strain was effective in reducing the risk of acute myocardial infarction in elderly persons: a population-based study. Medicine (Baltimore) 2016; 95:e2869.
    1. Foster ED, Cavanaugh JE, Haynes WG, et al. . Acute myocardial infarctions, strokes and influenza: seasonal and pandemic effects. Epidemiol Infect 2013; 141:735–44.
    1. Kelly H, Birch C. The causes and diagnosis of influenza-like illness. Aust Fam Physician 2004; 33:305–9.
    1. Zhao H, Harris RJ, Ellis J, Donati M, Pebody RG. Epidemiology of parainfluenza infection in England and Wales, 1998–2013: any evidence of change?Epidemiol Infect 2017; 145:1210–20.
    1. Field TS, Zhu H, Tarrant M, Mitchell JR, Hill MD. Relationship between supra-annual trends in influenza rates and stroke occurrence. Neuroepidemiology 2004; 23:228–35.
    1. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010; 10:83–92.
    1. Lee N, Chan PK, Lui GC, et al. . Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza?J Infect Dis 2011; 203:1739–47.
    1. Bautista E, Chotpitayasunondh T, Gao Z, et al. . Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708–19.
    1. Grau AJ, Fischer B, Barth C, Ling P, Lichy C, Buggle F. Influenza vaccination is associated with a reduced risk of stroke. Stroke 2005; 36:1501–6.
    1. Liu JC, Wang TJ, Sung LC, et al. . Influenza vaccination reduces hemorrhagic stroke risk in patients with atrial fibrillation: a population-based cohort study. Int J Cardiol 2017; 232:315–23.
    1. Lavallée PC, Labreuche J, Fox KM, et al. ; PERFORM, OPTIC, and AMISTAD Investigators Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke. Neurology 2014; 82:1905–13.
    1. Booth S, Baleriola C, Rawlinson WD. Comparison of two rapid influenza A/B test kits with reference methods showing high specificity and sensitivity for influenza A infection. J Med Virol 2006; 78:619–22.
    1. Wang XL, Yang L, Chan KP, et al. . Model selection in time series studies of influenza-associated mortality. PLoS One 2012; 7:e39423.
    1. Corrales-Medina VF, Suh KN, Rose G, et al. . Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011; 8:e1001048.
    1. Jefferson T, Jones MA, Doshi P, et al. . Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; 4:CD008965.
    1. Rae N, Finch S, Chalmers JD. Cardiovascular disease as a complication of community-acquired pneumonia. Curr Opin Pulm Med 2016; 22:212–8.
    1. Ren S, Hure A, Peel R, et al. ; AUSPICE Study Group Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: the Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). Am Heart J 2016; 177:58–65.
    1. Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, Pietri PG, Stefanadis CI. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol 2015; 22:1185–99.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel